Provider: Wright Reports
Swedish Orphan Biovitrum publ AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Swedish Orphan Biovitrum publ AB's Kiobrina pivotal phase three study did not meet primary endpoint
Swedish Orphan Biovitrum publ AB:Announces topline data from its pivotal phase three study of its enzyme therapy Kiobrina (rhBSSL - recombinant human Bile Salt Stimulated Lipase).Primary endpoint of the study - growth velocity measured after four weeks of treatment with rhBSSL - was not met.No statistically significant improvement in growth velocity was demonstratedin preterm infants treated with rhBSSL compared to placebo.
Latest Developments for Swedish Orphan Biovitrum publ AB
- Swedish Orphan Biovitrum publ AB maintains FY 2014 financial guidance
- FDA approves Swedish Orphan Biovitrum and Biogen Idec Eloctate
- Swedish Orphan Biovitrum elects Ernst & Young as auditor
- Swedish Orphan Biovitrum and Biogen Idec announce positive efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate for haemophilia A
- Share this
- Digg this